TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19526752
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional Western medicine alone)
Study: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (108 mg)
Study: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (36 mg)
Study: 18190583
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (not specified dosage)
Study: 15668544
Drug: efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz (EFV) 600 mg once daily
Study: 15668544
Drug: nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine (NVP) 200 mg twice daily
Study: 15668544
Drug: nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine (NVP) 400 mg once daily
Study: 15668544
Drug: nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nevirapine (NVP) 400 mg once daily + efavirenz (EFV) 800 mg once daily
Study: 15668544
Drug: NVP 200
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 200 mg twice daily
Study: 15668544
Drug: NVP 400
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 400 mg once daily
Study: 15668544
Drug: NVP 400
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP 400 mg once daily + EFV 800 mg once daily
Study: 10199943
Drug: Gamma-scintigraphy with
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-scintigraphy with light tablet (12 mm, different isotope)
Study: 10199943
Drug: Gamma-scintigraphy with
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-scintigraphy with dense tablet (12 mm, different isotope)
Study: 7796241
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine ointment
Study: 7796241
Drug: 30% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% lignocaine ointment
Study: 7796241
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (no treatment)
Study: 19514
Drug: Carbuterol 2
Normalized name: albuterol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbuterol 2 mg
Study: 19514
Drug: Carbuterol 4
Normalized name: albuterol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbuterol 4 mg
Study: 23834587
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI)
Study: 21143465
Drug: Topical niacin
Normalized name: niacin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical niacin pretreatment with 585-nm pulsed dye laser (PDL)
Study: 16492205
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 microg) administered at -60 min relative to a standardized breakfast meal
Study: 16492205
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 microg) administered at -15 min relative to a standardized breakfast meal
Study: 16492205
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 microg) administered at 0 min relative to a standardized breakfast meal
Study: 16492205
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 microg) administered at +30 min relative to a standardized breakfast meal
Study: 16492205
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 microg) administered at +60 min relative to a standardized breakfast meal
Study: 16492205
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at -15 min relative to a standardized breakfast meal
Study: 6379788
Drug: Salbutamol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.4 mg)
Study: 6379788
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg) and Salbutamol (0.4 mg)
Study: 31833799
Drug: PepCan HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepCan HPV therapeutic vaccine
Study: 25406657
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg three times weekly (tiw)
Study: 25406657
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg daily
Study: 25406657
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg daily
Study: 23080039
Drug: Conventional tabletop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tabletop therapy
Study: 20212343
Drug: Kidney transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney transplant recipients with detectable levels of Anti-CMV IgG antibodies
Study: 20212343
Drug: Kidney transplant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney transplant recipients with anti-CMV IgM antibodies
Study: 18596311
Drug: L-alanyl-L-glutamine-supplemented parenteral
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-L-glutamine-supplemented parenteral nutrition (PN)
Study: 16048758
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% gel once-a-day
Study: 16048758
Drug: Clindamycin 1%
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% solution twice-a-day
Study: 7746978
Drug: Four treatment
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four treatment regimens
Study: 1961956
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg, intravenously)
Study: 1961956
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental (5 mg/kg, intravenously)
Study: 7042481
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 25 mg
Study: 7042481
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 50 mg
Study: 7042481
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 100 mg
Study: 27861546
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition (1000 ml/24 h, 700 kcal)
Study: 27861546
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous nutrition)
Study: 17906008
Drug: Low-dose E2/levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose E2/levonorgestrel (0.023 mg/d 17beta-estradiol and 0.0075 mg/d levonorgestrel)
Study: 17906008
Drug: Micro-dose E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-dose E2 (0.014 mg/d 17beta-estradiol)
Study: 17906008
Drug: Micro-dose E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-dose E2
Study: 15772925
Drug: 2.27% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.27% glucose dialysis solution
Study: 15772925
Drug: 3.86% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.86% glucose dialysis solution
Study: 11893366
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg administered daily for 6 weeks)
Study: 9916601
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 25 mg
Study: 26279411
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg
Study: 9916601
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 100 mg
Study: 7842147
Drug: Continuation phase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation phase of treatment with antidepressant medication
Study: 7842147
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication as per AHCPR guidelines
Study: 2221313
Drug: Thiopentone 3‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 3‐6 mg/kg
Study: 2221313
Drug: Propofol 1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1‐3 mg/kg mixed with lignocaine (10/200 mg)
Study: 2221313
Drug: Propofol 1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1‐3 mg/kg followed by alfentanil 0.01 mg/kg
Study: 750185
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg suppository
Study: 750185
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg suppository
Study: 29297555
Drug: 4% TiF4‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4‐gel applied once (TiF41)
Study: 29297555
Drug: 4% TiF4‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4‐gel applied twice (TiF42)
Study: 29297555
Drug: 4% TiF4‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% TiF4‐gel applied three times (TiF43)
Study: 25929594
Drug: Eltrombopag 12.5
Normalized name: eltrombopag 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 12.5 mg once daily
Study: 25929594
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg once daily
Study: 25929594
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg once daily
Study: 25929594
Drug: Dose-titration regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-titration regimen
Study: 25929594
Drug: Fixed doses
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed doses of eltrombopag (12.5, 25, 50, 75 mg once daily)
Study: 23259702
Drug: Post-teriparatide group
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Post-teriparatide group (after 72 weeks of teriparatide injections)
Study: 23259702
Drug: Post-placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-placebo group (after 72 weeks of placebo injections)
Study: 23259702
Drug: Bisphosphonates treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates treatment after teriparatide
Study: 19054188
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1.7 g DHA and 0.6 g EPA per day)
Study: 19054188
Drug: Placebo (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.6 g linoleic acid per day)
Study: 16702317
Drug: Carob fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carob fiber (0, 5, 10, or 20 g)
Study: 16702317
Drug: Carob fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carob fiber (20 g)
Study: 11731509
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics prescribed on an around-the-clock (ATC) basis
Study: 11731509
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics prescribed on an as-needed (PRN) basis
Study: 1619382
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg daily)
Study: 30063280
Drug: Immediate-loaded mini
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-loaded mini dental implants
Study: 30063280
Drug: Immediate-loaded conventional-size
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-loaded conventional-size dental implants
Study: 24974075
Drug: Treatment (ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (ondansetron 8mg as required)
Study: 19962227
Drug: Degarelix 240
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg for 1 month, then 80 mg monthly
Study: 17433027
Drug: Standard-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose lenograstim (263 microg/d)
Study: 17433027
Drug: Low-dose lenograstim
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lenograstim (105 microg/d)
Study: 7624987
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg of ofloxacin
Study: 26289352
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for 6 months
Study: 9239449
Drug: Sublingual spray
Normalized name: Myoden, sublingual spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray of 0.4 mg GTN (two puffs)
Study: 9239449
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet of 0.5 mg GTN
Study: 8421980
Drug: Nifedipine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (administered to 20 patients: 8 in group 1, 12 in group 2)
Study: 8421980
Drug: Metoprolol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (administered to 21 patients: 9 in group 1, 12 in group 2)
Study: 3334056
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily for 4 weeks
Study: 3334056
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg twice daily for 4 weeks
Study: 3334056
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily and Acebutolol 200 mg twice daily in combination for 4 weeks
Study: 3334056
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Nifedipine and Acebutolol)
Study: 18251757
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (Arnica montana 5 CH, Bryonia alba 5 CH, Hypericum perforatum 5 CH, Ruta graveolens 3 DH)
Study: 16513246
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen treatment (25-mcg estradiol vaginal tablet or 1g conjugated estrogen cream intravaginally daily for 2 weeks, then twice a week for 10 weeks)
Study: 16513246
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen treatment
Study: 12589396
Drug: Bupropion (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (100-200 mg/day)
Study: 12589396
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day) in 10 depressed patients
Study: 8854287
Drug: Silicol gel
Normalized name: silicon dioxide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicol gel
Study: 8967905
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg t.i.d.
Study: 6692648
Drug: Intravenous cefoperazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefoperazone (CFP)
Study: 20510972
Drug: Brain Injury
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain Injury Coping Skills Group (12-session, manualized cognitive-behavioral treatment)
Study: 16603132
Drug: Bromocriptine (D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (D2 agonist)
Study: 12923400
Drug: Trimethaphan 2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethaphan 2‐4 mg/min (autonomic blockade)
Study: 9201796
Drug: Abecarnil 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 5.0 mg
Study: 9201796
Drug: Abecarnil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil 2.5 mg
Study: 1443511
Drug: Ketanserin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (0.3 mg.kg‐1 bolus followed by 0.06 mg.kg‐1.h‐1 infusion)
Study: 29993224
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with nasal irrigation of normal saline (4 times daily) and nasal corticosteroids (one puff in each nostril daily)
Study: 25355484
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (2 × 1 g/d)
Study: 25355484
Drug: Control (soya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (soya bean oil, 2 × 1 g/d)
Study: 21311484
Drug: Cytoflavin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin treatment (20 ml in 400 ml of 0.9% NaCl solution twice a day intravenously for days 1-10; 850 mg twice a day for days 11-35)
Study: 21311484
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic therapy aimed at improving systemic hemodynamics, rheological blood properties, and prevention of stroke complications)
Study: 29957664
Drug: Low-Level Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Light Therapy (LLLT)
Study: 29957664
Drug: Sham light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham light treatment
Study: 20973770
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with methyl aminolaevulinate
Study: 16503684
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g.kg(‐1) for 7 days)
Study: 12695317
Drug: Lamotrigine (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (100-400 mg daily)
Study: 14628976
Drug: Lithium (0.8-1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (0.8-1.1 mEq/L)
Study: 23721245
Drug: CP/fosbretabulin (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP/fosbretabulin (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks, with fosbretabulin 60 mg/m² on days 1, 8, and 15)
Study: 23721245
Drug: CP (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks)
Study: 21219810
Drug: Acetaminophen +
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen + B vitamins
Study: 20878408
Drug: Theophylline 200
Normalized name: theophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 200 mg IV before the procedure
Study: 15644641
Drug: 6 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/kg tidal volume strategy
Study: 15644641
Drug: 12 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL/kg tidal volume strategy
Study: 7799895
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment (6 month course)
Study: 3352195
Drug: Multivitamin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin preparation without lidocaine
Study: 3352195
Drug: Multivitamin preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin preparation with 1% lidocaine
Study: 3352195
Drug: Excipient formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient formulation without vitamins (isoosmotic)
Study: 3352195
Drug: Excipient formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient formulation without vitamins (with saline)
Study: 27038098
Drug: Perampanel (2–12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (2–12 mg/day, once daily at bedtime)
Study: 27038098
Drug: Perampanel (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (12 mg)
Study: 27038098
Drug: Perampanel (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (not specified dosage)
Study: 25351220
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of sodium hyaluronate
Study: 23566577
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of intravenous antibiotics (G1)
Study: 23566577
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of intravenous antibiotics (G2)
Study: 20458051
Drug: Adjuvant classical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Study: 12825916
Drug: Direct hypnosis
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct hypnosis with standard medical treatment
Study: 12825916
Drug: Indirect hypnosis
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect hypnosis with standard medical treatment
Study: 12825916
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control with standard medical treatment
Study: 1711250
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 50 mg b.i.d.
Study: 29308939
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (standard treatment plus application of Kinesio Taping on the respiratory muscles)
Study: 24965569
Drug: Rilotumumab 15
Normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab 15 mg/kg plus ECX
Study: 24965569
Drug: Rilotumumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab 7.5 mg/kg plus ECX
Study: 24965569
Drug: Combined rilotumumab
Normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rilotumumab (both doses) plus ECX
Study: 20171420
Drug: NXN-188 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXN-188 (doses of 2 to 800 mg, 0.027-11.2 mg/kg)